Researchers at Mayo Clinic have established new criteria for diagnosing a memory-loss syndrome in older adults, known as Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), which impacts the brain’s limbic system and is often mistaken for Alzheimer’s disease. These criteria provide a framework for more precise diagnosis and treatment, offering hope for better management of symptoms and tailored therapies for patients.
Mayo Clinic researchers have defined new criteria for Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), a memory-loss condition in older adults that mimics Alzheimer’s but progresses more slowly and has a better prognosis, aiding in more accurate diagnosis and treatment.
Researchers at the Mayo Clinic have established new criteria for a memory-loss syndrome in older adults that specifically affects the brain’s limbic system. Often mistaken for Alzheimer’s disease, Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS) progresses more slowly and has a better prognosis. This newly defined syndrome provides clearer guidelines for doctors working to diagnose and treat patients with memory loss.
Prior to the researchers developing clinical criteria published in the journal Brain Communications, the hallmarks of the syndrome could be confirmed only by examining brain tissue after a person’s death. The proposed criteria provide a framework for neurologists and other experts to classify the condition in patients living with symptoms, offering a more precise diagnosis and potential treatments. They consider factors such as age, severity of memory impairment, brain scans, and biomarkers indicating the deposits of specific proteins in the brain.
The criteria were developed and validated using data from more than 200 participants in databases for the Mayo Clinic Alzheimer’s Disease Research Center, the Mayo Clinic Study of Aging, and the Alzheimer’s Disease Neuroimaging Initiative.
Benefits of Understanding LANS
Understanding the condition will lead to better management of symptoms and more tailored therapies for patients suffering from this type of cognitive decline, distinct from Alzheimer’s disease, says David T. Jones, M.D., a Mayo Clinic neurologist and senior author of the study.
“In our clinical work, we see patients whose memory symptoms appear to mimic Alzheimer’s disease, but when you look at their brain imaging or biomarkers, it’s clear they don’t have Alzheimer’s. Until now, there has not been a specific medical diagnosis to point to, but now we can offer them some answers,” Jones says. “This research creates a precise framework that other medical professionals can use to care for their patients. It has major implications for treatment decisions, including amyloid-lowering drugs and new clinical trials, and counseling on their prognosis, genetics, and other factors.”
Decades of work to understand and classify different types of dementia is ongoing, says Nick Corriveau-Lecavalier, Ph.D., the paper’s first author. These findings build upon scientists’ continued efforts to untangle neurological conditions that often have similar symptoms or can occur simultaneously, but can have drastically different treatments and prognoses.
“Historically, you might see someone in their 80s with memory problems and think they may have Alzheimer’s disease, and that is often how it’s being thought of today,” Corriveau-Lecavalier says. “With this paper, we are describing a different syndrome that happens much later in life. Often, the symptoms are restricted to memory and will not progress to impact other cognitive domains, so the prognosis is better than with Alzheimer’s disease.”
Without signs of Alzheimer’s disease, the researchers looked at the involvement of one possible culprit – a buildup of a protein called TDP-43 in the limbic system that scientists have found in the autopsied brain tissue of older adults. Researchers have classified the build-up of these protein deposits as limbic-predominant age-related TDP-43 encephalopathy, or LATE. These protein deposits could be associated with the newly defined memory loss syndrome, but there are also other likely causes and more research is needed, the authors say.
With clinical criteria established by Jones, Corriveau-Lecavalier, and co-authors, practitioners could soon diagnose LANS in patients so those living with memory loss might better understand options for treatment and potential progression of the disease, opening doors for research to further illuminate the characteristics of the disease.
Reference: “Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome” by Nick Corriveau-Lecavalier, Hugo Botha, Jonathan Graff-Radford, Aaron R Switzer, Scott A Przybelski, Heather J Wiste, Melissa E Murray, Robert Ross Reichard, Dennis W Dickson, Aivi T Nguyen, Vijay K Ramanan, Stuart J McCarter, Bradley F Boeve, Mary M Machulda, Julie A Fields, Nikki H Stricker, Peter T Nelson, Michel J Grothe, David S Knopman, Val J Lowe, Ronald C Petersen, Clifford R Jack and David T Jones, 17 July 2024, Brain Communications.
DOI: 10.1093/braincomms/fcae183
The research was funded in part by National Institutes of Health grants P30 AG062677, P50 AG016574, U01 AG006786, R37 AG011378 and R01 AG041851 and by the Robert Wood Johnson Foundation, the Elsie and Marvin Dekelboum Family Foundation, the Liston Family Foundation, the Edson Family, the Gerald A. and Henrietta Rauenhorst Foundation and the Foundation Dr. Corinne Schuler.
Drs. Jones and Corriveau-Lecavalier reported no conflicts of interest.
Be the first to comment on "Mayo Clinic Defines New Memory Loss Syndrome Affecting Older Adults"